<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmedpharm</journal-id><journal-title-group><journal-title xml:lang="ru">Фармация и фармакология</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacy &amp; Pharmacology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2307-9266</issn><issn pub-type="epub">2413-2241</issn><publisher><publisher-name>Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.19163/2307-9266-2020-8-1-40-47</article-id><article-id custom-type="elpub" pub-id-type="custom">pmedpharm-622</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ И ТОКСИКОЛОГИЧЕСКАЯ ХИМИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL AND TOXICOLOGICAL CHEMISTRY</subject></subj-group></article-categories><title-group><article-title>ВЭЖХ-методика количественного анализа фексофенадина в печени кроликов</article-title><trans-title-group xml:lang="en"><trans-title>HPLC methods of fexofenadine quantitative analysis in rabbits’ liver</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7829-2494</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мыльников</surname><given-names>П. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Mylnikov</surname><given-names>P. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мыльников Павел Юрьевич – ассистент кафедры фармакологии с курсом фармации факультета дополнительного профессионального образования</p><p>390026, Россия, Рязань, Высоковольтная, 9</p></bio><bio xml:lang="en"><p>Pavel Yu. Mylnikov – Assistant, Department of Pharmacology with a course of pharmacy, Faculty of Continuing Professional Education</p><p>9, Vysokovoltnaya St., Ryazan, Russia, 390026</p></bio><email xlink:type="simple">pavelmylnikov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5618-7607</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черных</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernykh</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черных Иван Владимирович – кандидат биологических наук, заведующий кафедрой фармацевтической химии</p><p>390026, Россия, Рязань, Высоковольтная, 9</p></bio><bio xml:lang="en"><p>Ivan V. Chernykh – Candidate of Sciences (Biology), Head of the Department of Pharmaceutical Chemistry</p><p>9, Vysokovoltnaya St., Ryazan, Russia, 390026</p></bio><email xlink:type="simple">ivchernykh88@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1688-0017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щулькин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchulkin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щулькин Алексей Владимирович – кандидат медицинских наук, доцент кафедры фармакологии с курсом фармации факультета дополнительного профессионального образования</p><p>390026, Россия, Рязань, Высоковольтная, 9</p></bio><bio xml:lang="en"><p>Aleksey V. Shchulkin – Candidate of Sciences (Medicine), Associate Professor of the Department of Pharmacology with a course of pharmacy, Faculty of Continuing Professional Education</p><p>9, Vysokovoltnaya St., Ryazan, Russia, 390026</p></bio><email xlink:type="simple">alekseyshulkin@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5166-8372</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Попова Наталья Михайловна – кандидат медицинских наук, доцент кафедры фармакологии с курсом фармации факультета дополнительного профессионального образования</p><p>390026, Россия, Рязань, Высоковольтная, 9</p></bio><bio xml:lang="en"><p>Natalia M. Popova – Candidate of Sciences (Medicine), Assistant Professor of the Department of Pharmacology with a Pharmacy Course, Faculty of Continuing Professional Education</p><p>9, Vysokovoltnaya St., Ryazan, Russia, 390026</p></bio><email xlink:type="simple">p34-66@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6887-4888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Якушева</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakusheva</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Якушева Елена Николаевна – доктор медицинских наук, профессор, заведующая кафедрой фармакологии с курсом фармации факультета дополнительного профессионального образования</p><p>390026, Россия, Рязань, Высоковольтная, 9</p></bio><bio xml:lang="en"><p>Elena N. Yakusheva – Doctor of Sciences (Medicine), Professor, Head of the Department of Pharmacology with a Pharmacy Course, Faculty of Continuing Professional Education</p><p>9, Vysokovoltnaya St., Ryazan, Russia, 390026</p></bio><email xlink:type="simple">e.yakusheva@rzgmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Рязанский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ryazan State Medical University n. a. Acad. Pavlov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>03</day><month>05</month><year>2020</year></pub-date><volume>8</volume><issue>1</issue><fpage>40</fpage><lpage>47</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мыльников П.Ю., Черных И.В., Щулькин А.В., Попова Н.М., Якушева Е.Н., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Мыльников П.Ю., Черных И.В., Щулькин А.В., Попова Н.М., Якушева Е.Н.</copyright-holder><copyright-holder xml:lang="en">Mylnikov P.Y., Chernykh I.V., Shchulkin A.V., Popova N.M., Yakusheva E.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmpharm.ru/jour/article/view/622">https://www.pharmpharm.ru/jour/article/view/622</self-uri><abstract><p>Исследование фармакокинетики маркерных субстратов белка-транспортера гликопротеина-Р (Pgp, ABCB1-белка), к которым относится фексофенадин, является одним из способов оценки его функциональной активности.</p><sec><title>Цель</title><p>Цель. Разработка ВЭЖХ-методики количественного определения фексофенадина в печени кроликов.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Количественное определение фексофенадина осуществляли с использованием хроматографической системы Stayer («Аквилон», Россия) с УФ детектором UVV 104. Применяли обращенно-фазную хроматографическую колонку Luna C18 100Å (250*4,6) с зернением 5 мкм при температуре 45°С. Определение концентрации фексофенадина проводили методом абсолютной калибровки по площади пиков.</p></sec><sec><title>Результаты</title><p>Результаты. Исследование проводили в изократическом режиме. Состав подвижной фазы: вода деионизированная, ацетонитрил и ледяная уксусная кислота в соотношении 267,4:120:4,33, доведенные триэтиламином до pH=6,7. Пробоподготовка заключалась в гомогенизации 500 мг измельченной печени в 500 мкл воды очищенной с последующим центрифугированием (1750 g) и отбором надосадочной жидкости. Осаждение белка осуществлялось ацетонитрилом (2,5 мл), подкисленным 375 мкл кислоты хлористоводородной путем встряхивания на приборе Shaker (500 об./мин). Надосадочный слой переносили в отдельную пробирку, добавляли по 2 мл метилена хлористого, эфира диэтилового и этилацетата и повторно встряхивали 10 мин (при 500 об./мин). Затем центрифугировали (1750 g) и упаривали супернатант на роторно-вакуумном испарителе при 50°С. К сухому остатку добавляли 300 мкл подвижной фазы и 100 мкл инжектировали в хроматограф. Метод был валидирован в линейном диапазоне от 3 до 60 мкг/г фексофенадина с приемлемой внутри- и межцикловой точностью, прецизионностью и стабильностью. Методика была апробирована на кроликах после внутривенного введения им фексофенадина в дозе 11 мг/кг массы.</p></sec><sec><title>Заключение</title><p>Заключение. Разработана ВЭЖХ-методика количественного определения фексофенадина в ткани печени кроликов, которая может использоваться для оценки функциональной активности Pgp в доклинических исследованиях.</p></sec><sec><title>Список сокращений</title><p>Список сокращений: Pgp − гликопротеин-Р, ВЭЖХ – высокоэффективная жидкостная хроматография, об./мин – оборотов в минуту</p></sec></abstract><trans-abstract xml:lang="en"><p>The investigation of pharmacokinetics of marker substrates of carrier protein P-glycoprotein (Pgp, ABCB1-protein) including fexofenadine, is one of the methods of its functional activity evaluation.</p><p>The aim of the study was to work out the HPLC methods of the quantitative determination of fexofenadine in rabbits’ liver.</p><sec><title>Materials and methods</title><p>Materials and methods. The quantitative determination of fexofenadine was performed using Stayer chromatographic system (Akvilon, Russia) with UVV 104 ultraviolet detector. Reverse-phased chromatographic column Luna C18 100Å (250*4.6) was used with 5 µm granulation at 45°С. The сoncentration of fexofenadine was determined by methods of absolute peak area calibration.</p></sec><sec><title>Results</title><p>Results. The work was conducted in the isocratic mode. The composition of the mobile phase consisted of deionized water, acetonitrile and glacial acetic acid at the ratio of 267.4:120:4.33 brought to pH=6.7 with triethylamine. The sample processing was in the form of homogenization of 500 mg of ground liver in 500 µl of purified water with the subsequent centrifugation (1750 g) and selection of the supernatant. The proteins were precipitated by acetonitrile (2.5 ml) acidified with 375 µl of hydrochloric acid by shaking at 500 rev/min. The supernatant was transported into a separate test tube, where methylene chloride, diethyl ether and ethyl acetate were added (2 ml each). Then the solution was again shaken for 10 minutes (500 rev/min). After that, the solution was centrifuged (1750 g) and the supernatant was evaporated on a rotor-vacuum evaporator at 50°С. 300 µl of the mobile phase was added to the dry residue, and 100 µl was injected into the chromatograph. The method was validated in the linear range from 3 to 60 µg/g of fexofenadine with the acceptable intra- and intercycle accuracy, precision and stability. The method was tested on rabbits after the intravenous administration of fexofenadine at the dose of 11 mg/kg.</p></sec><sec><title>Conclusion</title><p>Conclusion. The HPLC methods of fexofenadine quantitative determination in the hepatic tissue of rabbits has been worked out. It can be used for the evaluation of the functional activity of Pgp in preclinical studies.</p></sec><sec><title>Abbreviations</title><p>Abbreviations: Pgp – P-glycoprotein, HPLC – high performance liquid chromatography, rev/min – revolutions per minute</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гликопротеин-Р</kwd><kwd>АВСВ1-белок</kwd><kwd>фексофенадин</kwd><kwd>хроматография</kwd><kwd>фармакокинетика</kwd><kwd>кролики</kwd><kwd>печень</kwd></kwd-group><kwd-group xml:lang="en"><kwd>P-glycoprotein</kwd><kwd>АВСВ1-protein</kwd><kwd>fexofenadine</kwd><kwd>chromatography</kwd><kwd>pharmacokinetics</kwd><kwd>rabbits</kwd><kwd>liver</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа поддержана грантом Российского фонда фундаментальных исследований № А 18-015-00259.</funding-statement><funding-statement xml:lang="en">This work was supported by a grant from the Russian Foundation for Basic Research No. A 18-015-00259.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sharom F.J. The P-glycoprotein multidrug transporter // Essays. Biochem. 2011. V. 50. P. 161–178. DOI: 0.1042/bse0500161</mixed-citation><mixed-citation xml:lang="en">Sharom FJ. The P-glycoprotein multidrug transporter. 2011;50:161–78. DOI: 0.1042/bse0500161</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mollazadeh S., Sahebkar A., Hadizadeh F., Behravan J., Arabzadeh S. Structural and functional aspects of P-glycoprotein and its inhibitors [Text] // Life Sci. 2018. Vol. 214. P. 118–123. DOI: 10.1016/j.lfs.2018.10.048</mixed-citation><mixed-citation xml:lang="en">Mollazadeh S, Sahebkar A, Hadizadeh F, Behravan J, Arabzadeh S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 2018;214:118–23. DOI: 10.1016/j.lfs.2018.10.048</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кукес В.Г., Грачев С.В., Сычев Д.А., Раменская Г.В. Метаболизм лекарственных средств. Научные основы персонализированной медицины: руководство для врачей. М.: ГЭОТАР-МЕДиа, 2008. 304 c.</mixed-citation><mixed-citation xml:lang="en">Kukes VG, Grachev SV, Sychev DA, Ramenskaya GV. Metabolizm lekarstvennykh sredstv. Nauchnyye osnovy personalizirovannoy meditsiny: rukovodstvo dlya vrachey [The metabolism of drugs. The Scientific Basics of Personalized Medicine: A Guide for Physicians]. Moscow: GEOTAR-MEDIA; 2008. 304 p. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chufan E.E., Sim H.M., Ambudkar S.V. Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies // Adv. Cancer Res. 2015. Vol. 125. P. 71–96. DOI: 10.1016/bs.acr.2014.10.003</mixed-citation><mixed-citation xml:lang="en">Chufan EE, Sim HM, Ambudkar SV. Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies. Adv Cancer Res. 2015;125:71–96. DOI: 10.1016/bs.acr.2014.10.003</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Черных И.В., Щулькин А.В., Гацанога М.В., Попова Н.М., Есенина А.С., Градинарь М.М., Якушева Е.Н. Функциональная активность гликопротеина-P на фоне ишемии головного мозга // Наука молодых - Eruditio Juvenium. 2019. Т. 7. № 1. С. 46–52. DOI: 10.23888/hmj20197146-52</mixed-citation><mixed-citation xml:lang="en">Chernykh IV, Shchulkin AV, Gatsanoga MV, Popova NM, Yesenina AS, Gradinar MM, Yakusheva EN. Funktsional’naya aktivnost’ glikoproteina-P na fone ishemii golovnogo mozga [Functional activity of P-glycoprotein with underlying brain ischemia]. Nauka molodykh – Eruditio Juvenium. 2019;7(1):46–52. DOI: 10.23888/hmj20197146-52. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Якушева Е.Н., Сычев Д.А., Щулькин А.В., Черных И.В., Ма- рия Валериевна Гацанога М.В. Оценка принадлежности лекарственных препаратов к ингибиторам и индукторам белка-транспортера гликопротеина-P в эксперименте in vivo // Экспер.и клин. фармакол. 2018. Т. 81. № 1. С. 17–23.</mixed-citation><mixed-citation xml:lang="en">Yakusheva EN, Sychev DA, Shchulkin AV, Chernykh IV, Gatsanoga MV. Otsenka prinadlezhnosti lekarstvennykh preparatov k ingibitoram i induktoram belka-transportera glikoproteina-P v eksperimente in vivo [In vivo assessment of drugs belonging to inhibitors and inductors of P-glycoprotein]. Exp and Clin Pharmacol. 2018;81(1):17–23. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Методические рекомендации по изучению биотрансформации и транспортеров новых лекарственных средств: дизайн исследований, анализданных. Руководство по экспертизе лекарственных средств. Том III. М.: Гриф и К, 2014. 343 с.</mixed-citation><mixed-citation xml:lang="en">Metodicheskiye rekomendatsii po izucheniyu biotransformatsii i transporterov novykh lekarstvennykh sredstv: dizayn issledovaniy, analizdannykh. Rukovodstvo po ekspertize lekarstvennykh sredstv. Tom III. [Guidelines for the study of biotransformation and transporters of new drugs: research design, data analysis. Guidelines for the examination of medicines. Vol. III]. Moscow: Grif i K; 2014. 343 p. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">U.S. Food and Drug Administration, Center for Drug Evaluationand Research. Guidance for industry: drug interaction studiesdstudy design, data analysis, implications for dosing, and labeling recommendations. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (дата обращения: 15.01.2018)</mixed-citation><mixed-citation xml:lang="en">U.S. Food and Drug Administration, Center for Drug Evaluationand Research. Guidance for industry: drug interaction studiesdstudy design, data analysis, implications for dosing, and labeling recommendations [cited 2018 Jan 15] Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Раменская Г.В., Скуридина Е.А., Красных Л.М. Разработка методики количественного определения маркера активности P-гликопротеина фексофенадина в плазме крови // Хим.-фарм. журн. 2006. Т. 40. № 12. С. 47–50.</mixed-citation><mixed-citation xml:lang="en">Ramenskaya GV, Skuridina EA, Krasnykh LM. Razrabotka metodiki kolichestvennogo opredeleniya markera aktivnosti P-glikoproteina feksofenadina v plazme krovi [Developing a method for the quantitative determination of the P-glycoprotein activity marker fexofenadine in blood plasma]. Pharm Chem J. 2006;40(12):47–50. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Якушева Е.Н., Черных И.В., Щулькин А.В., Гацанога М.В. Разработка ВЭЖХ-методики количественного анализа фексофенадина в плазме крови // Фармакокинетика и фармакодинамика. 2017. № 2. С. 35–38.</mixed-citation><mixed-citation xml:lang="en">Yakusheva EN, Chernykh IV, Shulkin AV, Gatsanoga MV. Razrabotka metodiki kolichestvennogo analiza feksofenadina v plazme krovi [Design of HPLC methods of fexofenadine quantitative analysis in blood plasma]. Pharmacokinetics and pharmacodynamics. 2017;2:35–8. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Черных И.В., Щулькин А.В., Мыльников П.Ю., Гацанога М.В., Попова Н.М., Якушева Е.Н. Метод анализа функциональной активности гликопротеина-P в гематоэнцефалическом барьере // Нейрохимия. 2019. Т. 36. № 1. С. 84–88. DOI: 10.1134/S1027813319010060</mixed-citation><mixed-citation xml:lang="en">Chernykh IV, Shchulkin AV, Mylnikov PYu, Gatsanoga MV, Popova NM, Yakusheva EN. Metod analiza funktsional’noy aktivnosti glikoproteina-P v gematoentsefalicheskom bar’yere [Method of analysis of functional activity of P-glycoprotein in the blood-brain barrier]. Neurochem J. 2019;36(1):84–8. DOI: 10.1134/S1027813319010060. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bosilkovska M. Samer C.F., Déglon J., Rebsamen M., Staub C., Dayer P., Walder B., Desmeules J.A., Daali Y. Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots // Clin. Pharmacol. Ther. 2014. Vol. 96. No 3. P. 349–359. DOI: 10.1038/clpt.2014.83</mixed-citation><mixed-citation xml:lang="en">Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Daye P, Walder B, Desmeules JA, Daali Y. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014;96(3):349–59. DOI: 10.1038/clpt.2014.83.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Muppavarapu R., Guttikar S., Rajappan M., Kamarajan K., Mullangi R. Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study // Biomed. Chromatogr. 2014. Vol. 28. No 8. P. 1048–1056. DOI: 10.1002/bmc.3114</mixed-citation><mixed-citation xml:lang="en">Muppavarapu R, Guttikar S, Rajappan M, Kamarajan K, Mullangi R. Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. Biomed Chromatogr. 2014; 28(8):1048–1056.  doi.org/10.1002/bmc.3114</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по содержанию и использованию лабораторных животных. Восьмое издание / пер. с англ. под ред. И.В. Белозерцевой, Д.В. Блинова, М.С. Красильщиковой. М.: ИРБИС, 2017. 336 с.</mixed-citation><mixed-citation xml:lang="en">Belozertseva IV, Blinov DV, Krasil’shchikova MS. Rukovodstvo po soderzhaniyu i ispol’zovaniyu laboratornykh zhivotnykh. Vos’moye izdaniye [Guidelines for the maintenance and use of laboratory animals. Eighth edition]. Moscow: IRBIS;2017. 336 p. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Изучение биоэквивалентности воспроизведенных лекарственных средств. Руководство по экспертизе лекарственных средств. Том I. М.: Гриф и К, 2013. 328 с.</mixed-citation><mixed-citation xml:lang="en">Izucheniye bioekvivalentnosti vosproizvedennykh lekarstvennykh sredstv. Rukovodstvo po ekspertize lekarstvennykh sredstv. Tom I [The study of bioequivalence reproduced drugs. Guidelines for the examination of medicines. Vol. I]. Moscow: Grif i K; 2013. 328 p. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Guidance for Industry: Bioanalytical method validation (draft guidance). U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER). U.S. Government Printing Office: Washington, DC, 2013. URL: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (дата обращения: 15.01.2018)</mixed-citation><mixed-citation xml:lang="en">Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM); London, 2013. 28p.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on bioanalytical method validation. European Medicines Agency. Committee for medicinal products for human use. London, 2011. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf (дата обращения: 15.01.2018)</mixed-citation><mixed-citation xml:lang="en">Guideline on bioanalytical method validation. European Medicines Agency. Committee for medicinal products for human use: London; 2011. [cited 2018 Jan 15] [23 p]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-meth-od-validation_en.pdf</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Эпштейн Н.А. Оценка пригодности (валидация) ВЭЖХ методик в фармацевтическом анализе (обзор) // Хим.- фарм. журн. 2004. Т. 38. № 4. С. 40–56.</mixed-citation><mixed-citation xml:lang="en">Epstein NA. Otsenka prigodnosti (validatsiya) vezhkh metodik v farmatsevticheskom analize (obzor) [Suitability evaluation (validation) HPLC methods in pharmaceutical analysis (review)]. Pharm Chem J. 2004;38(4):40–56. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Якушева Е.Н., Черных И.В., Щулькин А.В., Гацанога М.В. Методика определения принадлежности лекарственных средств к числу субстратов гликопротеина-P // Росс. мед.-биол. вестн. им. акад. И.П. Павлова. 2015. Т. 23. № 3. С. 49–53.</mixed-citation><mixed-citation xml:lang="en">Yakusheva EN, Chernykh IV, Shulkin AV, Gatsanoga MV. Metodika opredeleniya prinadlezhnosti lekarstvennykh sredstv k chislu substratov glikoproteina-P [Methods of identification of drugs as P-glycoprotein substrates]. IP Pavlov Russian Medical Biological Herald. 2015;23(3):49–53. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Molimard М., Diquet B., Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans // Fund. &amp; Clin. Pharmacol. 2004. Vol. 18. No 4. P. 399–411. DOI: 10.1111/j.1472-8206.2004.00254.x</mixed-citation><mixed-citation xml:lang="en">Molimard М, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fund &amp; Clin Pharmacol. 2004;18(4):399–411. DOI: 10.1111/j.1472-8206.2004.00254.x</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ballent M., Wilkens M.R., Mate L., Muscher A.S., Virkel G., Sallovitz J., Schröder B., Lanusse C., Lifschitz A. P-glycoprotein in sheep liver and small intestine: gene expression and transport efflux activity // J. Vet. Pharmacol. Ther. 2013. Vol. 36. No 6. Р. 576–582. DOI: 10.1111/jvp.12040</mixed-citation><mixed-citation xml:lang="en">Ballent M, Wilkens MR, Mate L, Mushar AS, Virkel G, Sallovitz J, Schroder B, Lanusse C, Lifschitz A. P-glycoprotein in sheep liver and small intestine: gene expression and transport efflux activity. J Vet Pharmacol Ther. 2013;36(6):576–82. DOI: 10.1111/jvp.12040</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hagenbuch B., Gao B., Meier P.J. Transport of Xenobiotics Across the Blood-Brain Barrier // News Physiol. Sci. 2002. No. 17. P. 231–234. DOI: 10.1152/nips.01402.2002</mixed-citation><mixed-citation xml:lang="en">Hagenbuch B, Gao B, Meier PJ. Transport of Xenobiotics Across the Blood-Brain Barrier. News Physiol Sci. 2002;17:231–4. DOI: 10.1152/nips.01402.2002</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">van Veen H.W., Margolles A., Muller M., Higgins C.F., Konings W.N. The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism // EMBO J. 2000. Vol. 19. P. 2503–2514.</mixed-citation><mixed-citation xml:lang="en">van Veen HW, Margolles A, Muller M, Higgins CF, Konings WN. The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO J. 2000;19:2503–14.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Le Cluysell E.L. Pregnane X receptor: molecular basis for special differences in CYP3A induction by xenobiotics // Chem. Biol. Interact. 2001. Vol. 134. No 3. P. 283–289.</mixed-citation><mixed-citation xml:lang="en">Le Cluysell EL. Pregnane X receptor: molecular basis for special differences in CYP3A induction by xenobiotics. Chem Biol Interact. 2001;134(3):283–9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Moore L.B., Maglich J.M., McKee D.D., Wisely B., Willson T.M., Kliewer S.A., Lambert M.H., Moore J.T. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors // Mol. Endocrine. 2002. Vol. 16. No 5. P. 977–986. DOI: 10.1210/mend.16.5.0828</mixed-citation><mixed-citation xml:lang="en">Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol endocrin. 2002;16(5):977–86. DOI: 10.1210/mend.16.5.0828</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
